Boston Tech
Vertex Expanded Casgevy to Age 2, and Boston's CRISPR Future Now Comes in Toddler Sizes
Vertex's July 1 FDA expansion makes Casgevy available to children ages 2 and up, a major Boston biotech milestone with real access hurdles.
Boston Tech
Vertex's July 1 FDA expansion makes Casgevy available to children ages 2 and up, a major Boston biotech milestone with real access hurdles.
Boston Tech
Cambridge-based Flare Therapeutics raised $85 million on June 30 to push a first-in-class prostate cancer program after years of transcription-factor homework.
Boston Tech
Waltham-based Cogent filed an NDA for bezuclastinib in advanced systemic mastocytosis, turning a rare-disease bet into a serious 2026 launch race.
Boston Tech
Cambridge-based Moderna unveiled mRNA-6007, an in vivo CAR-T bet on lupus and related autoimmune disease that could make cell therapy less bespoke.
Boston Tech
Boston Dynamics will invest $100 million in a new Waltham robotics and AI center, adding 1,250 jobs by 2033 in a serious Massachusetts flex.
Boston Tech
MIT's new Gleanmer chip maps 3D space for tiny robots at under 6 milliwatts, giving Boston robotics another deeply practical flex.
Boston Tech
A positive check-in on the Massachusetts AI Coalition, Ryan Durkin's organizing work at WHOOP, and Boston's AI momentum.
Boston Tech
AbbVie is buying Waltham-based Apogee for $10.9 billion, turning a long-acting eczema antibody into Boston biotech's latest serious exit.
Boston Tech
HyperLight raised $80 million on June 18 to scale Cambridge-built photonics for AI infrastructure, turning Boston optics into a real data-center bet.
Boston Tech
Spero Therapeutics won FDA approval for the first oral carbapenem in the U.S., giving Cambridge biotech a real answer to hospital-only UTI care.
Boston Tech
Foundation Alloy raised $22 million on June 16 to scale MIT-born solid-state metallurgy in Massachusetts with a new facility and Japan distribution.
Boston Tech
Akamai's new agentic security framework aims to verify AI shopping agents at the edge, giving Cambridge a concrete, very Boston AI story.